Skip to main content
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. — Investor Relations & Filings

Ticker · VVOS ISIN · US92859E1082 US Manufacturing
Open in API
Filings indexed 260 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country US United States of America
Listing US VVOS

About Vivos Therapeutics, Inc.

https://vivos.com/

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company's core offering is The Vivos System, a non-surgical treatment that uses proprietary oral appliances. These devices are designed to address underlying dentofacial abnormalities that can restrict the airway. The treatment protocol aims to promote the natural growth and development of the jaw and airway in both adult and pediatric patients. Vivos provides its technology and training to a network of licensed dentists and medical professionals who deliver the therapy.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 88% confidence The document is a U.S. SEC Form 8-K “Current Report,” containing Items 1.01, 2.03, 3.01, 3.02 (material definitive agreement, new obligations, delisting notice, unregistered securities). It is a periodic regulatory compliance filing rather than a standalone financial report, management discussion, or transaction notice category defined elsewhere. Therefore, it falls into the catch-all Regulatory Filings category (RNS).
2026-06-08 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-20 English
424B3 - Vivos Therapeutics, Inc. (0001716166) (Filer)
Regulatory Filings Classification · 75% confidence The document is a full SEC Form 424B3 prospectus registering the resale of shares issuable upon exercise of warrants. It is not an annual or interim financial report, not a management or earnings release, nor an AGM or proxy statement. There is no executive management change, legal proceeding, dividend notice or merger activity. It is a regulatory filing (a prospectus) that does not fit into other more specific categories, so it falls into the general Regulatory Filings category (RNS).
2026-05-08 English
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
Delisting Announcement Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Vivos Therapeutics, Inc. The key content is an Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. It discusses the company's failure to meet Nasdaq's minimum stockholders' equity requirement, the steps taken to remedy this, and the potential consequences including delisting. The document is a regulatory announcement about the company's listing status and compliance with exchange rules, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the delisting notice and company actions. Therefore, the appropriate classification is Delisting Announcement (DLST).
2026-04-22 English
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
Regulatory Filings
2026-04-15 English
10-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
Annual Report FY 2025
2026-04-15 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.